Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYAD: Switching to Dolutegravir/Lamivudine in HIV
NCT04585737Phase 4Completed
- Start
- Oct 2020
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1). Started Oct 2020; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04585737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585737.